PL353033A1 - Szczepionka przeciwko wirusowi HIV-1, zawierającacałość lub część białka TAT HIV-1 - Google Patents

Szczepionka przeciwko wirusowi HIV-1, zawierającacałość lub część białka TAT HIV-1

Info

Publication number
PL353033A1
PL353033A1 PL00353033A PL35303300A PL353033A1 PL 353033 A1 PL353033 A1 PL 353033A1 PL 00353033 A PL00353033 A PL 00353033A PL 35303300 A PL35303300 A PL 35303300A PL 353033 A1 PL353033 A1 PL 353033A1
Authority
PL
Poland
Prior art keywords
hiv
protein
tat
vaccine
entire
Prior art date
Application number
PL00353033A
Other languages
English (en)
Other versions
PL197666B1 (pl
Inventor
Erwann Loret
Original Assignee
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904610A external-priority patent/FR2792204B1/fr
Application filed by Centre National De La Recherche Scientifique (Cnrs) filed Critical Centre National De La Recherche Scientifique (Cnrs)
Publication of PL353033A1 publication Critical patent/PL353033A1/pl
Publication of PL197666B1 publication Critical patent/PL197666B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL353033A 1999-04-13 2000-04-12 Szczepionka anty-HIV-1, sposób wytwarzania poliklonalnych przeciwciał anty-TAT, sposób wykrywania obecności białka TAT w próbce biologicznej, zestaw do diagnozowania zakażenia HIV i sposób wytwarzania wariantu TAT PL197666B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904610A FR2792204B1 (fr) 1999-04-13 1999-04-13 Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
FR9916633A FR2792206B1 (fr) 1999-04-13 1999-12-29 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
PCT/FR2000/000938 WO2000061067A2 (fr) 1999-04-13 2000-04-12 Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1

Publications (2)

Publication Number Publication Date
PL353033A1 true PL353033A1 (pl) 2003-10-06
PL197666B1 PL197666B1 (pl) 2008-04-30

Family

ID=26234914

Family Applications (1)

Application Number Title Priority Date Filing Date
PL353033A PL197666B1 (pl) 1999-04-13 2000-04-12 Szczepionka anty-HIV-1, sposób wytwarzania poliklonalnych przeciwciał anty-TAT, sposób wykrywania obecności białka TAT w próbce biologicznej, zestaw do diagnozowania zakażenia HIV i sposób wytwarzania wariantu TAT

Country Status (20)

Country Link
US (1) US7087377B2 (pl)
EP (1) EP1169057B1 (pl)
JP (1) JP4860823B2 (pl)
KR (1) KR100725637B1 (pl)
AT (1) ATE280586T1 (pl)
AU (1) AU775560B2 (pl)
BR (1) BR0009758A (pl)
CA (1) CA2370563C (pl)
DE (1) DE60015312T2 (pl)
DK (1) DK1169057T3 (pl)
ES (1) ES2231178T3 (pl)
FR (1) FR2792206B1 (pl)
HK (1) HK1044463B (pl)
HU (1) HUP0200841A2 (pl)
IL (2) IL145884A0 (pl)
MX (1) MXPA01010482A (pl)
NO (1) NO326603B1 (pl)
PL (1) PL197666B1 (pl)
PT (1) PT1169057E (pl)
WO (1) WO2000061067A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100465589B1 (ko) * 2001-04-20 2005-01-13 허만욱 비만 억제 폴리펩타이드
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
CA2722240C (en) * 2008-04-22 2016-09-20 Centre National De La Recherche Scientifique Tat protein for preventing or treating aids
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011128720A1 (en) * 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2928910B1 (en) 2012-12-06 2019-09-04 PIN Pharma, Inc. Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5019510A (en) 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
AU710626B2 (en) * 1995-03-08 1999-09-23 Neovacs Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation process and pharmaceutical compositions comprising them
DE19514089C2 (de) * 1995-04-13 1997-07-10 Deutsches Krebsforsch Nachweisverfahren für HIV-TAT
JPH10212300A (ja) * 1996-11-26 1998-08-11 Sankyo Co Ltd ペプチドワクチン
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
ATE280586T1 (de) 2004-11-15
KR100725637B1 (en) 2007-06-07
FR2792206A1 (fr) 2000-10-20
NO20014841D0 (no) 2001-10-04
ES2231178T3 (es) 2005-05-16
DK1169057T3 (da) 2005-03-07
WO2000061067A2 (fr) 2000-10-19
AU3972400A (en) 2000-11-14
DE60015312D1 (de) 2004-12-02
WO2000061067B1 (fr) 2001-05-10
EP1169057B1 (fr) 2004-10-27
JP2002541165A (ja) 2002-12-03
CA2370563A1 (fr) 2000-10-19
HK1044463B (zh) 2005-06-03
US20050106161A1 (en) 2005-05-19
HUP0200841A2 (en) 2002-07-29
US7087377B2 (en) 2006-08-08
FR2792206B1 (fr) 2006-08-04
NO326603B1 (no) 2009-01-19
BR0009758A (pt) 2002-01-08
PT1169057E (pt) 2005-03-31
AU775560B2 (en) 2004-08-05
WO2000061067A3 (fr) 2001-03-29
CA2370563C (fr) 2013-12-17
JP4860823B2 (ja) 2012-01-25
PL197666B1 (pl) 2008-04-30
KR20020005675A (ko) 2002-01-17
HK1044463A1 (en) 2002-10-25
MXPA01010482A (es) 2002-09-18
IL145884A (en) 2007-09-20
EP1169057A2 (fr) 2002-01-09
NO20014841L (no) 2001-11-27
IL145884A0 (en) 2002-07-25
DE60015312T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
IL145884A0 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
AU1685499A (en) Polypeptide, their production and use
FI891716A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat käyttökelpoisia AIDS'in hoidossa
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
FI893962A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat hyödyllisiä AIDS:in hoidossa
FI955315A7 (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n ho itoon
EP0676954A4 (en) HIV LOCK VIRUS.
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
MY134041A (en) Novel composition
BR0114912A (pt) Kahalalide f
WO2002035981A3 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
HRP20000400B1 (hr) Transmukozni pripravci levosimendana
IT1312569B1 (it) Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
BG101175A (bg) Тройна анти-нiv комбинация
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
WO2000027880A3 (en) Rantes-derived peptides with anti-hiv activity
BR0108723A (pt) Medicamentos contra doenças viróticas
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
EP1096021A3 (en) Melanins with improved ability to inhibit HIV replication
DE60210936D1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert